Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
NCT ID: NCT00289237
Last Updated: 2012-10-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
61301 participants
Study Classification
INTERVENTIONAL
Study Start Date
1999-03-31
Study Completion Date
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In spite of declining trend coronary heart disease (CHD) is still a leading cause of morbidity and mortality. Many years of epidemiological research have identified several risk factors for CHD. The main causes are physical inactivity and inappropriate diet (mediated through high blood pressure, high cholesterol and fatness) and smoking. So far intervention studies on lifestyle factors have shown disappointing results, most probably due to insufficient interventions and methodology.
Inter99 is a randomized non-pharmacological intervention study comprising 61,301 persons representing a well-defined population. About 13,000 are invited for a health examination and assessment of risk for CHD. Those at high risk are offered lifestyle intervention in three waves over a five year period. A priori the group is divided into a high intensive and low intensive intervention group. The remaining 48.285 individuals serve as control.
After five years all individuals who attended the base-line examination are re-invited to assess the effect of the intervention on intermediate end-points as lifestyle, absolute risk of CHD and biological risk factors. The total cohort (61.301) is followed through central registers to evaluate the effect of the intervention on use of the health care system and the long term effect on incidence of CHD.
The status for the project is that the four waves of intervention have been performed, the last follow-up was in March 2006.
Data collection finalized with 10 years follow-up via Central National Registries and a questionnaire. No further follow-up is scheduled for the main purposes of the study.
Analyses as regard the primary effect (on incidence of cardiovascular diseases) and secondary effect (on incidence of type 2 diabetes) are on-going. Analyses for a large number of spin off project are on-going.
More than 25 Ph.d. studies and more than 200 peer-review publication have so far been produced.
Summary of results, links to articles and theses at: www.Inter99.dk
Inter99 is a randomized non-pharmacological intervention study comprising 61,301 persons representing a well-defined population. About 13,000 are invited for a health examination and assessment of risk for CHD. Those at high risk are offered lifestyle intervention in three waves over a five year period. A priori the group is divided into a high intensive and low intensive intervention group. The remaining 48.285 individuals serve as control.
After five years all individuals who attended the base-line examination are re-invited to assess the effect of the intervention on intermediate end-points as lifestyle, absolute risk of CHD and biological risk factors. The total cohort (61.301) is followed through central registers to evaluate the effect of the intervention on use of the health care system and the long term effect on incidence of CHD.
The status for the project is that the four waves of intervention have been performed, the last follow-up was in March 2006.
Data collection finalized with 10 years follow-up via Central National Registries and a questionnaire. No further follow-up is scheduled for the main purposes of the study.
Analyses as regard the primary effect (on incidence of cardiovascular diseases) and secondary effect (on incidence of type 2 diabetes) are on-going. Analyses for a large number of spin off project are on-going.
More than 25 Ph.d. studies and more than 200 peer-review publication have so far been produced.
Summary of results, links to articles and theses at: www.Inter99.dk
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In spite of declining trend coronary heart disease (CHD) is still a leading cause of morbidity and mortality. Many years of epidemiological research have identified several risk factors for CHD. The main causes are physical inactivity and inappropriate diet (mediated through high blood pressure, high cholesterol and fatness) and smoking. So far intervention studies on lifestyle factors have shown disappointing results.
Inter99 is a randomized non-pharmacological intervention study comprising 61,301 persons representing a well-defined population. About 13,000 are invited for a health examination and assessment of risk for CHD. Those at high risk are offered lifestyle intervention in three waves over a five year period. A priori the group is divided into a high intensive and low intensive intervention group. The remaining 48.285 individuals serve as control.
After five years all individuals who attended the base-line examination are re-invited to assess the effect of the intervention on intermediate end-points as lifestyle, absolute risk of CHD and biological risk factors. The total cohort (61.301) is followed through central registers to evaluate the effect of the intervention on use of the health care system and the long term effect on incidence of CHD.
Inter99 is a randomized non-pharmacological intervention study comprising 61,301 persons representing a well-defined population. About 13,000 are invited for a health examination and assessment of risk for CHD. Those at high risk are offered lifestyle intervention in three waves over a five year period. A priori the group is divided into a high intensive and low intensive intervention group. The remaining 48.285 individuals serve as control.
After five years all individuals who attended the base-line examination are re-invited to assess the effect of the intervention on intermediate end-points as lifestyle, absolute risk of CHD and biological risk factors. The total cohort (61.301) is followed through central registers to evaluate the effect of the intervention on use of the health care system and the long term effect on incidence of CHD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
CHD
AMI
CVD
Type 2 Diabetes
COLD
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Lifestyle intervention
Behavioural changes
CHD
Type 2 diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High intensity intervention group
Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.
Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up
Group Type
EXPERIMENTAL
Lifestyle intervention
Intervention Type
BEHAVIORAL
Low intensity intervention group
Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.
Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up
Group Type
EXPERIMENTAL
Lifestyle intervention
Intervention Type
BEHAVIORAL
Control group
Questionnaires regarding lifestyle and general health were sent to all participants in this group.
The importance of healthy lifestyle was not mentioned, and no intervention was offered.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lifestyle intervention
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All citizens in a predefined area
Exclusion Criteria
* Drug abuse
* Language problem
* Language problem
Minimum Eligible Age
30 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steno Diabetes Center Copenhagen
OTHER
Sponsor Role
collaborator
Glostrup University Hospital, Copenhagen
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Birgitte Pickering
B. Pickering is the secretary of Professor Torben Joergensen, who is the primary investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Torben Jørgensen, DrMedSci
Role: PRINCIPAL_INVESTIGATOR
Research Centre for Prevention and Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Centre for Prevention and Health
Glostrup Municipality, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Glumer C, Jorgensen T, Borch-Johnsen K; Inter99 study. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003 Aug;26(8):2335-40. doi: 10.2337/diacare.26.8.2335.
Reference Type
BACKGROUND
Husemoen LL, Thomsen TF, Fenger M, Jorgensen HL, Jorgensen T. Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2). Genet Epidemiol. 2003 May;24(4):322-30. doi: 10.1002/gepi.10239.
Reference Type
BACKGROUND
Jorgensen ME, Glumer C, Bjerregaard P, Gyntelberg F, Jorgensen T, Borch-Johnsen K; Grennland Population Study. Obesity and central fat pattern among Greenland Inuit and a general population of Denmark (Inter99): relationship to metabolic risk factors. Int J Obes Relat Metab Disord. 2003 Dec;27(12):1507-15. doi: 10.1038/sj.ijo.0802434.
Reference Type
BACKGROUND
Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil. 2003 Oct;10(5):377-86. doi: 10.1097/01.hjr.0000096541.30533.82.
Reference Type
BACKGROUND
Nielsen EM, Hansen L, Echwald SM, Drivsholm T, Borch-Johnsen K, Ekstrom CT, Hansen T, Pedersen O. Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics. 2003 Jul;13(7):417-23. doi: 10.1097/01.fpc.0000054105.48725.5c.
Reference Type
BACKGROUND
Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K; inter99 study. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004 Mar;27(3):727-33. doi: 10.2337/diacare.27.3.727.
Reference Type
BACKGROUND
Glumer C, Jorgensen T, Borch-Johnsen K. Targeted screening for undiagnosed diabetes reduces the number of diagnostic tests. Inter99(8). Diabet Med. 2004 Aug;21(8):874-80. doi: 10.1111/j.1464-5491.2004.01260.x.
Reference Type
BACKGROUND
Hansen SK, Gjesing AP, Rasmussen SK, Glumer C, Urhammer SA, Andersen G, Rose CS, Drivsholm T, Torekov SK, Jensen DP, Ekstrom CT, Borch-Johnsen K, Jorgensen T, McCarthy MI, Hansen T, Pedersen O. Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release. Diabetologia. 2004 Jun;47(6):1079-87. doi: 10.1007/s00125-004-1418-3. Epub 2004 May 29.
Reference Type
BACKGROUND
Johansen A, Nielsen EM, Andersen G, Hamid YH, Jensen DP, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia. 2004 Aug;47(8):1437-41. doi: 10.1007/s00125-004-1459-7. Epub 2004 Jul 17.
Reference Type
BACKGROUND
Andersen KL, Echwald SM, Larsen LH, Hamid YH, Glumer C, Jorgensen T, Borch-Johnsen K, Andersen T, Sorensen TI, Hansen T, Pedersen O. Variation of the McKusick-Kaufman gene and studies of relationships with common forms of obesity. J Clin Endocrinol Metab. 2005 Jan;90(1):225-30. doi: 10.1210/jc.2004-0465. Epub 2004 Oct 13.
Reference Type
BACKGROUND
Husemoen LL, Thomsen TF, Fenger M, Jorgensen T. Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype. Inter99 (7). Eur J Clin Nutr. 2004 Aug;58(8):1142-50. doi: 10.1038/sj.ejcn.1601942.
Reference Type
BACKGROUND
Kessel L, Hougaard JL, Mortensen C, Jorgensen T, Lund-Andersen H, Larsen M. Visual acuity and refractive errors in a suburban Danish population: Inter99 Eye Study. Acta Ophthalmol Scand. 2004 Feb;82(1):19-24. doi: 10.1111/j.1395-3907.2004.0179.x.
Reference Type
BACKGROUND
Andersen G, Wegner L, Yanagisawa K, Rose CS, Lin J, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Hansen T, Spiegelman BM, Pedersen O. Evidence of an association between genetic variation of the coactivator PGC-1beta and obesity. J Med Genet. 2005 May;42(5):402-7. doi: 10.1136/jmg.2004.026278.
Reference Type
BACKGROUND
Andersen G, Wegner L, Jensen DP, Glumer C, Tarnow L, Drivsholm T, Poulsen P, Hansen SK, Nielsen EM, Ek J, Mouritzen P, Vaag A, Parving HH, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites. Hypertension. 2005 Apr;45(4):565-70. doi: 10.1161/01.HYP.0000158946.53289.24. Epub 2005 Feb 28.
Reference Type
BACKGROUND
Hansen SK, Nielsen EM, Ek J, Andersen G, Glumer C, Carstensen B, Mouritzen P, Drivsholm T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes. J Clin Endocrinol Metab. 2005 Jun;90(6):3629-37. doi: 10.1210/jc.2004-1942. Epub 2005 Mar 29.
Reference Type
BACKGROUND
Rose CS, Andersen G, Hamid YH, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. Studies of relationships between the GLUT10 Ala206Thr polymorphism and impaired insulin secretion. Diabet Med. 2005 Jul;22(7):946-9. doi: 10.1111/j.1464-5491.2005.01547.x.
Reference Type
BACKGROUND
Ek J, Rose CS, Jensen DP, Glumer C, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. The functional Thr130Ile and Val255Met polymorphisms of the hepatocyte nuclear factor-4alpha (HNF4A): gene associations with type 2 diabetes or altered beta-cell function among Danes. J Clin Endocrinol Metab. 2005 May;90(5):3054-9. doi: 10.1210/jc.2004-2159. Epub 2005 Feb 22.
Reference Type
BACKGROUND
Faerch K, Lau C, Tetens I, Pedersen OB, Jorgensen T, Borch-Johnsen K, Glumer C. A statistical approach based on substitution of macronutrients provides additional information to models analyzing single dietary factors in relation to type 2 diabetes in danish adults: the Inter99 study. J Nutr. 2005 May;135(5):1177-82. doi: 10.1093/jn/135.5.1177.
Reference Type
BACKGROUND
Lau C, Faerch K, Glumer C, Tetens I, Pedersen O, Carstensen B, Jorgensen T, Borch-Johnsen K; Inter99 study. Dietary glycemic index, glycemic load, fiber, simple sugars, and insulin resistance: the Inter99 study. Diabetes Care. 2005 Jun;28(6):1397-403. doi: 10.2337/diacare.28.6.1397.
Reference Type
BACKGROUND
Glumer C, Borch-Johnsen K, Colagiuri S. Can a screening programme for diabetes be applied to another population? Diabet Med. 2005 Sep;22(9):1234-8. doi: 10.1111/j.1464-5491.2005.01641.x.
Reference Type
BACKGROUND
Hamid YH, Rose CS, Urhammer SA, Glumer C, Nolsoe R, Kristiansen OP, Mandrup-Poulsen T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia. 2005 Feb;48(2):251-60. doi: 10.1007/s00125-004-1623-0. Epub 2005 Jan 11.
Reference Type
BACKGROUND
Hamid YH, Vissing H, Holst B, Urhammer SA, Pyke C, Hansen SK, Glumer C, Borch-Johnsen K, Jorgensen T, Schwartz TW, Pedersen O, Hansen T. Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and Type 2 diabetes and insulin release. Diabet Med. 2005 Jan;22(1):74-80. doi: 10.1111/j.1464-5491.2005.01505.x.
Reference Type
BACKGROUND
Hamid YH, Urhammer SA, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. The common T60N polymorphism of the lymphotoxin-alpha gene is associated with type 2 diabetes and other phenotypes of the metabolic syndrome. Diabetologia. 2005 Mar;48(3):445-51. doi: 10.1007/s00125-004-1659-1. Epub 2005 Feb 24.
Reference Type
BACKGROUND
Hansen SK, Rose CS, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population. Diabetologia. 2005 Mar;48(3):452-8. doi: 10.1007/s00125-005-1671-0. Epub 2005 Feb 25.
Reference Type
BACKGROUND
Pisinger C, Vestbo J, Borch-Johnsen K, Thomsen T, Jorgensen T. Acceptance of the smoking cessation intervention in a large population-based study: the Inter99 study. Scand J Public Health. 2005;33(2):138-45. doi: 10.1080/14034940410028370.
Reference Type
BACKGROUND
Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. Smoking cessation intervention in a large randomised population-based study. The Inter99 study. Prev Med. 2005 Mar;40(3):285-92. doi: 10.1016/j.ypmed.2004.06.001.
Reference Type
BACKGROUND
Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev Med. 2005 Mar;40(3):278-84. doi: 10.1016/j.ypmed.2004.06.011.
Reference Type
BACKGROUND
Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. Smoking reduction intervention in a large population-based study. The Inter99 study. Prev Med. 2005 Jan;40(1):112-8. doi: 10.1016/j.ypmed.2004.05.014.
Reference Type
BACKGROUND
Torekov SS, Larsen LH, Glumer C, Borch-Johnsen K, Jorgensen T, Holst JJ, Madsen OD, Hansen T, Pedersen O. Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes. 2005 Jul;54(7):2261-5. doi: 10.2337/diabetes.54.7.2261.
Reference Type
BACKGROUND
Engelbrechtsen L, Mahendran Y, Jonsson A, Gjesing AP, Weeke PE, Jorgensen ME, Faerch K, Witte DR, Holst JJ, Jorgensen T, Grarup N, Pedersen O, Vestergaard H, Torekov S, Kanters JK, Hansen T. Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. BMC Genet. 2018 Mar 16;19(1):15. doi: 10.1186/s12863-018-0602-2.
Reference Type
DERIVED
Svendstrup M, Appel EVR, Sandholt CH, Ahluwalia TS, Angquist LH, Thuesen BH, Jorgensen ME, Pedersen O, Grarup N, Hansen T, Sorensen TIA, Vestergaard H. Prospective Studies Exploring the Possible Impact of an ID3 Polymorphism on Changes in Obesity Measures. Obesity (Silver Spring). 2018 Apr;26(4):747-754. doi: 10.1002/oby.22109. Epub 2018 Feb 14.
Reference Type
DERIVED
Hansen L, Netterstrom MK, Johansen NB, Ronn PF, Vistisen D, Husemoen LLN, Jorgensen ME, Rod NH, Faerch K. Metabolically Healthy Obesity and Ischemic Heart Disease: A 10-Year Follow-Up of the Inter99 Study. J Clin Endocrinol Metab. 2017 Jun 1;102(6):1934-1942. doi: 10.1210/jc.2016-3346.
Reference Type
DERIVED
Ahluwalia TS, Troelsen JT, Balslev-Harder M, Bork-Jensen J, Thuesen BH, Cerqueira C, Linneberg A, Grarup N, Pedersen O, Hansen T, Dalgaard LT. Carriers of a VEGFA enhancer polymorphism selectively binding CHOP/DDIT3 are predisposed to increased circulating levels of thyroid-stimulating hormone. J Med Genet. 2017 Mar;54(3):166-175. doi: 10.1136/jmedgenet-2016-104084. Epub 2016 Sep 14.
Reference Type
DERIVED
Lau CJ, Pisinger C, Husemoen LLN, Jacobsen RK, Linneberg A, Jorgensen T, Glumer C. Effect of general health screening and lifestyle counselling on incidence of diabetes in general population: Inter99 randomised trial. Prev Med. 2016 Oct;91:172-179. doi: 10.1016/j.ypmed.2016.08.016. Epub 2016 Aug 8.
Reference Type
DERIVED
Bender AM, Jorgensen T, Pisinger C. Effects of general health checks differ under two different analyses perspectives-the Inter99 randomized study. J Clin Epidemiol. 2016 Mar;71:120-2. doi: 10.1016/j.jclinepi.2015.11.008. Epub 2015 Nov 18. No abstract available.
Reference Type
DERIVED
Bender AM, Kawachi I, Jorgensen T, Pisinger C. Neighborhood social capital is associated with participation in health checks of a general population: a multilevel analysis of a population-based lifestyle intervention- the Inter99 study. BMC Public Health. 2015 Jul 22;15:694. doi: 10.1186/s12889-015-2042-5.
Reference Type
DERIVED
Baumann S, Toft U, Aadahl M, Jorgensen T, Pisinger C. The long-term effect of screening and lifestyle counseling on changes in physical activity and diet: the Inter99 Study - a randomized controlled trial. Int J Behav Nutr Phys Act. 2015 Mar 6;12:33. doi: 10.1186/s12966-015-0195-3.
Reference Type
DERIVED
Krarup NT, Borglykke A, Allin KH, Sandholt CH, Justesen JM, Andersson EA, Grarup N, Jorgensen T, Pedersen O, Hansen T. A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 Danish individuals. Atherosclerosis. 2015 Jun;240(2):305-10. doi: 10.1016/j.atherosclerosis.2015.03.022. Epub 2015 Mar 16.
Reference Type
DERIVED
Dashti HS, Follis JL, Smith CE, Tanaka T, Cade BE, Gottlieb DJ, Hruby A, Jacques PF, Lamon-Fava S, Richardson K, Saxena R, Scheer FA, Kovanen L, Bartz TM, Perala MM, Jonsson A, Frazier-Wood AC, Kalafati IP, Mikkila V, Partonen T, Lemaitre RN, Lahti J, Hernandez DG, Toft U, Johnson WC, Kanoni S, Raitakari OT, Perola M, Psaty BM, Ferrucci L, Grarup N, Highland HM, Rallidis L, Kahonen M, Havulinna AS, Siscovick DS, Raikkonen K, Jorgensen T, Rotter JI, Deloukas P, Viikari JS, Mozaffarian D, Linneberg A, Seppala I, Hansen T, Salomaa V, Gharib SA, Eriksson JG, Bandinelli S, Pedersen O, Rich SS, Dedoussis G, Lehtimaki T, Ordovas JM. Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants. Am J Clin Nutr. 2015 Jan;101(1):135-43. doi: 10.3945/ajcn.114.095026. Epub 2014 Nov 26.
Reference Type
DERIVED
Skaaby T, Nystrup Husemoen LL, Roswall N, Thuesen BH, Linneberg A. Atopy and development of cancer: a population-based prospective study. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):779-85. doi: 10.1016/j.jaip.2014.06.010. Epub 2014 Aug 28.
Reference Type
DERIVED
Aadahl M, Linneberg A, Moller TC, Rosenorn S, Dunstan DW, Witte DR, Jorgensen T. Motivational counseling to reduce sitting time: a community-based randomized controlled trial in adults. Am J Prev Med. 2014 Nov;47(5):576-86. doi: 10.1016/j.amepre.2014.06.020. Epub 2014 Aug 8.
Reference Type
DERIVED
Jorgensen T, Jacobsen RK, Toft U, Aadahl M, Glumer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ. 2014 Jun 9;348:g3617. doi: 10.1136/bmj.g3617.
Reference Type
DERIVED
Larsen SC, Angquist L, Ahluwalia TS, Skaaby T, Roswall N, Tjonneland A, Halkjaer J, Overvad K, Pedersen O, Hansen T, Linneberg A, Husemoen LL, Toft U, Heitmann BL, Sorensen TI. Dietary ascorbic acid and subsequent change in body weight and waist circumference: associations may depend on genetic predisposition to obesity--a prospective study of three independent cohorts. Nutr J. 2014 May 3;13:43. doi: 10.1186/1475-2891-13-43.
Reference Type
DERIVED
Larsen SC, Angquist L, Ahluwalia TS, Skaaby T, Roswall N, Tjonneland A, Halkjaer J, Overvad K, Pedersen O, Hansen T, Linneberg A, Husemoen LL, Toft U, Heitmann BL, Sorensen TIa. Interaction between genetic predisposition to obesity and dietary calcium in relation to subsequent change in body weight and waist circumference. Am J Clin Nutr. 2014 Apr;99(4):957-65. doi: 10.3945/ajcn.113.076596. Epub 2014 Feb 5.
Reference Type
DERIVED
Munch IC, Linneberg A, Larsen M. Precursors of age-related macular degeneration: associations with physical activity, obesity, and serum lipids in the inter99 eye study. Invest Ophthalmol Vis Sci. 2013 Jun 6;54(6):3932-40. doi: 10.1167/iovs.12-10785.
Reference Type
DERIVED
Toft U, Jakobsen M, Aadahl M, Pisinger C, Jorgensen T. Does a population-based multi-factorial lifestyle intervention increase social inequality in dietary habits? The Inter99 study. Prev Med. 2012 Jan;54(1):88-93. doi: 10.1016/j.ypmed.2011.10.005. Epub 2011 Oct 15.
Reference Type
DERIVED
Burgdorf KS, Gjesing AP, Grarup N, Justesen JM, Sandholt CH, Witte DR, Jorgensen T, Madsbad S, Hansen T, Pedersen O. Association studies of novel obesity-related gene variants with quantitative metabolic phenotypes in a population-based sample of 6,039 Danish individuals. Diabetologia. 2012 Jan;55(1):105-13. doi: 10.1007/s00125-011-2320-4. Epub 2011 Sep 28.
Reference Type
DERIVED
Pilgaard K, Faerch K, Carstensen B, Poulsen P, Pisinger C, Pedersen O, Witte DR, Hansen T, Jorgensen T, Vaag A. Low birthweight and premature birth are both associated with type 2 diabetes in a random sample of middle-aged Danes. Diabetologia. 2010 Dec;53(12):2526-30. doi: 10.1007/s00125-010-1917-3. Epub 2010 Sep 22.
Reference Type
DERIVED
Faerch K, Borch-Johnsen K, Vaag A, Jorgensen T, Witte DR. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia. 2010 May;53(5):858-65. doi: 10.1007/s00125-010-1673-4. Epub 2010 Feb 25.
Reference Type
DERIVED
Munch IC, Ek J, Kessel L, Sander B, Almind GJ, Brondum-Nielsen K, Linneberg A, Larsen M. Small, hard macular drusen and peripheral drusen: associations with AMD genotypes in the Inter99 Eye Study. Invest Ophthalmol Vis Sci. 2010 May;51(5):2317-21. doi: 10.1167/iovs.09-4482. Epub 2009 Dec 10.
Reference Type
DERIVED
Engberg S, Glumer C, Witte DR, Jorgensen T, Borch-Johnsen K. Differential relationship between physical activity and progression to diabetes by glucose tolerance status: the Inter99 Study. Diabetologia. 2010 Jan;53(1):70-8. doi: 10.1007/s00125-009-1587-1. Epub 2009 Nov 7.
Reference Type
DERIVED
Engberg S, Vistisen D, Lau C, Glumer C, Jorgensen T, Pedersen O, Borch-Johnsen K. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study. Diabetes Care. 2009 Apr;32(4):606-11. doi: 10.2337/dc08-1869. Epub 2008 Dec 29.
Reference Type
DERIVED
Toft U, Kristoffersen L, Ladelund S, Ovesen L, Lau C, Pisinger C, Smith Lv, Borch-Johnsen K, Jorgensen T. The effect of adding group-based counselling to individual lifestyle counselling on changes in dietary intake. The Inter99 study--a randomized controlled trial. Int J Behav Nutr Phys Act. 2008 Nov 21;5:59. doi: 10.1186/1479-5868-5-59.
Reference Type
DERIVED
Grarup N, Albrechtsen A, Ek J, Borch-Johnsen K, Jorgensen T, Schmitz O, Hansen T, Pedersen O. Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia. 2007 Jun;50(6):1201-8. doi: 10.1007/s00125-007-0668-2. Epub 2007 Apr 13.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.Inter99.dk
Study description and results. All publications available. Also in English.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCPH - 99-1
Identifier Type: -
Identifier Source: org_study_id